You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

18 Results
Guidelines and Advice
Status: Archived
ID: 6-18
Version: 2
Jun 2016
Guidelines and Advice
Status: Current
ID: 3-14
Version: 2
Sep 2016
Guidelines and Advice
Status: Current
ID: GL-C50-25
Feb 2016
Drug
Other Name(s): Busulfex® , Myleran®
Quick Link(s):
Drug Monograph
Jun 2019
Regimen
Cancer Type:
Genitourinary, 
Testis
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant, Curative
Drugs Used:
bleomycin,
etoposide,
CISplatin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2019
Regimen
Cancer Type:
Genitourinary, 
Testis
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant, Curative
Drugs Used:
bleomycin,
etoposide,
CISplatin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2019
Regimen
Cancer Type:
Genitourinary, 
Prostate
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
    bicalutamide
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
bicalutamide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2019
Regimen
Cancer Type:
Genitourinary, 
Prostate
Show More Show more tags
, Show Less Show fewer tags
Intent: Neoadjuvant, Adjuvant, Palliative
Funding:
ODB - General Benefit
  • buserelin
ODB - General Benefit
  • bicalutamide
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
buserelin,
bicalutamide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Oct 2016
Regimen
Cancer Type:
Genitourinary, 
Prostate
Show More Show more tags
, Show Less Show fewer tags
Intent: Neoadjuvant, Adjuvant, Palliative
Funding:
ODB - General Benefit
  • bicalutamide
ODB - General Benefit
  • goserelin
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
bicalutamide,
goserelin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Oct 2016
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Bortezomib - Previously Untreated - Multiple Myeloma
ODB - General Benefit
    melphalan - oral tablets
ODB - General Benefit
    prednisone
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
bortezomib,
melphalan,
prednisone
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2019
Regimen
Cancer Type:
Genitourinary, 
Prostate
Show More Show more tags
, Show Less Show fewer tags
Intent: Neoadjuvant, Adjuvant, Palliative
Funding:
ODB - General Benefit
  • buserelin
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
buserelin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Oct 2016
Regimen
Cancer Type:
Gynecologic, 
Germ Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Drugs Used:
PACLitaxel,
bleomycin,
etoposide,
CISplatin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2019

Pages